Amarin Corp plc (AMRN) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
May 5, 2016 7:03 AM EDTBEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/05/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2016, and provided an update on company operations.
Key Amarin achievements since December 31, 2015 include:
Revenue growth: Recognized $25.3 million in net product revenue from Vascepa® sales in Q1 2016 compared to $15.6 million in Q1 2015, an increase of approximately 63%;... More